Then, a 21-gene assay was recommended by the National Comprehensive Cancer Network to predict the risk of distant recurrence in patients with node-negative, estrogen receptor-positive BC who had been treated with tamoxifen [5]. The gene discussed is ESR1; the disease is breast cancer.